Samuelyan, Nora;
Ay, Pınar;
Moon, Zoe;
Sancar, Mesut;
Horne, Rob;
Okuyan, Betul;
(2024)
Reliability and validity of the Turkish version of the medication practical barriers to adherence questionnaire in patients with chronic diseases.
European Journal of Clinical Pharmacology
10.1007/s00228-024-03735-0.
(In press).
![[thumbnail of Moon_MPRAQ-TR manuscriptRV 19 July_zoe.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Moon_MPRAQ-TR manuscriptRV 19 July_zoe.pdf - Accepted Version Access restricted to UCL open access staff until 8 August 2025. Download (196kB) |
Abstract
Purpose: The aim of this study was to evaluate the validity and reliability of the Turkish version of the Medication Practical Barriers to Adherence Questionnaire (MPRAQ-TR). // Methods: This is a validation study conducted between August 2022 and March 2023 in the ambulatory services of a secondary care private hospital located in Istanbul, Türkiye, among patients (18 years of age and older) with chronic diseases. After the Turkish translation and cultural adaptation of the MPRAQ, and a pilot think-aloud study, the following psychometric properties were assessed: internal consistency by calculating the Cronbach’s alpha coefficient, 2-week test-retest reliability, convergent validity by calculating Spearman’s rank correlation between the MPRAQ-TR and the Turkish version of Medication Adherence Report Scale (MARS), and predictive validity by evaluating the association between the MPRAQ-TR score and nonadherence to medications. // Results: Among the 380 patients (response rate = 89.6%), 72.1% were nonadherent to their medications. The intraclass correlation coefficient was 0.99 for MPRAQ-TR scores (95% CI, 0.98–0.99; p < 0.001). The Cronbach’s alpha of the MPRAQ-TR was 0.853. There was a moderate negative correlation between the scores on the MARS and the MPRAQ-TR (Spearman’s rho = − 0.525; p < 0.01), supporting the convergent validity of the MPRAQ-TR. In the univariate analysis, the total score of MPRAQ-TR was associated with increased odds of nonadherence to medications (p < 0.01). // Conclusion: MPRAQ-TR shows good psychometric properties and can be used to evaluate the practical adherence barriers of patients with chronic diseases.
Archive Staff Only
 |
View Item |
